<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400890</url>
  </required_header>
  <id_info>
    <org_study_id>McCreary2020</org_study_id>
    <nct_id>NCT04400890</nct_id>
  </id_info>
  <brief_title>Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19</brief_title>
  <official_title>Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of Resveratrol, a Plant Polyphenol, for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marvin McCreary, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mount Carmel Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resveratrol is a plant polyphenol (that is sold commercially as a supplement) that might help&#xD;
      fight coronavirus as well as help protect the body from the effects of disease (COVID-19)&#xD;
      caused by the infection. In this proof-of-concept pilot study we will compare the effects of&#xD;
      resveratrol to placebo to assess the safety of the resveratrol and explore effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized placebo-controlled trial is for the outpatient treatment of COVID-19. The&#xD;
      purpose of this trial is to evaluate the safety and explore the effectiveness of resveratrol,&#xD;
      a plant polyphenol, being re-purposed for patients with early COVID-19. Published in vitro&#xD;
      data supports that this polyphenol inhibits coronavirus replication while separately&#xD;
      published in silico (computer molecular docking analysis) reports have identified specific&#xD;
      molecular targets of resveratrol against SARS-CoV2. Animal studies also demonstrate that&#xD;
      resveratrol is effective at preventing lung injury and death in certain animal models of&#xD;
      viral infections. Furthermore, the products long history as an anti-inflammatory might&#xD;
      prevent the cytokine storm that is associated with worse outcomes in COVID-19.&#xD;
&#xD;
      200 subjects, 45 and older, (100 receiving the plant polyphenol, 100 receiving placebo) will&#xD;
      be enrolled in study to compare whether taking resveratrol will reduce the rate of&#xD;
      hospitalization. Subjects will take capsules 4 times a day for a minimum of 7 days (up to 15&#xD;
      days depending on duration of symptoms) plus both groups will receive Vitamin D3 100,000 IU&#xD;
      to augment the effects of resveratrol. Resveratrol will be given as 1gm 4 times per day.&#xD;
      Placebo tablets will contain brown rice flour in visually identical capsules. The primary&#xD;
      outcome measure for this trial is reduction in hospitalization at 21 days from enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 12, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Actual">January 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization rates for COVID-19</measure>
    <time_frame>21 days from study randomization</time_frame>
    <description>Proportion of study participants admitted to the hospital within 21 days of randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Admission Rates</measure>
    <time_frame>21 days from randomization</time_frame>
    <description>Proportion of study participants admitted within 21 who subsequently get admitted to the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive Ventilation Rates</measure>
    <time_frame>21 days from randomization</time_frame>
    <description>Proportion of study participants who get admitted with 21 day of randomization who receiving invasive ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>21 days from randomization</time_frame>
    <description>Proportion of study participants are diagnosed with pneumonia with 21 day of randomization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>60 days from randomization</time_frame>
    <description>Diarrhea, nausea, abdominal cramping</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Resveratrol with Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resveratrol 1000mg four times per day for 15 days. Vitamin D3 100,000 IU on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Vitamin D3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules 4 times per day for 15 days. Vitamin D3 100,000 IU on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol vs placebo given for 15 days.</description>
    <arm_group_label>Resveratrol with Vitamin D3</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 100,000 IU given on day one.</description>
    <arm_group_label>Placebo with Vitamin D3</arm_group_label>
    <arm_group_label>Resveratrol with Vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients who test positive for infection with SARS-CoV-2.&#xD;
&#xD;
          -  Age ≥45 years&#xD;
&#xD;
          -  Mild COVID-19 based on WHO Baseline Severity Categorization&#xD;
&#xD;
          -  Symptom duration ≤ 10 days, or &lt;72 hours of new respiratory symptoms.&#xD;
&#xD;
          -  Patient must have access to the internet or a smartphone to complete surveys.&#xD;
&#xD;
          -  English-speaking patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed or suspected cognitive impairment that would prevent the patient from&#xD;
             cooperating with study procedures, as judged by the screening clinician&#xD;
&#xD;
          -  Asymptomatic patients (e.g. patients who were screened without symptoms but tested&#xD;
             positive)&#xD;
&#xD;
          -  Known or suspected liver disease or Hepatitis C&#xD;
&#xD;
          -  Known kidney disease with eGFR &lt;60&#xD;
&#xD;
          -  Patients on warfarin, Novel Oral Anticoagulants (NOACs), HIV Protease Inhibitors,&#xD;
             immunosuppressants, hydroxychloroquine/chloroquine, and other medication with a narrow&#xD;
             therapeutic window.&#xD;
&#xD;
          -  Allergy to grapes or rice.&#xD;
&#xD;
          -  Co-morbidities with a high likelihood of hospitalization within 30 days (e.g., current&#xD;
             cancer treatment, severe COPD or CHF)&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin R McCreary</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Carmel Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mt Carmel HealthSystems</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.supplement4covid19.com</url>
    <description>Recruitment website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mount Carmel Health System</investigator_affiliation>
    <investigator_full_name>Marvin McCreary, MD</investigator_full_name>
    <investigator_title>Emergency Physician</investigator_title>
  </responsible_party>
  <keyword>Coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID</keyword>
  <keyword>Vitamin D3</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Supplement</keyword>
  <keyword>Polyphenol</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Stilbene</keyword>
  <keyword>phytoalexin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

